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Preclinical evidence for an effective therapeutic
activity of FL118, a novel survivin inhibitor, in
patients with relapsed/refractory multiple myeloma
Over the past decades, immunomodulatory drugs, pro-
teasome inhibitors, and targeted antibodies have signifi-
cantly improved the overall survival of multiple myeloma
(MM) patients. Nonetheless, the disease remains incur-
able as patients ultimately develop resistance to all avail-
able modalities. One of the well-known mechanisms of
therapy resistance in MM is evasion of apoptosis, charac-
terized by an up-regulation of anti-apoptotic proteins of
the Bcl-2 family and/or inhibitor of apoptosis (IAP) pro-
teins including Survivin, whose expression is associated
with a worse clinical outcome.1,2 Apoptosis resistance can
be MM cell intrinsic, but can also be induced by their
interactions with accessory cells and the extracellular
matrix in the bone marrow (BM). Inside-out signaling via
integrins, signaling via NOTCH, or soluble factors like IL-
6, can significantly contribute to this microenvironment-
mediated drug resistance (EM-DR).3 To overcome apop-
tosis resistance, Li et al. have recently screened for com-
pounds that could alter the expression of Survivin in
tumor cells and described a new small molecule, FL118.4
Although FL118 was identified as a camptothecin analog,
it appeared to inhibit the promoter activity of Survivin
and its gene expression with significantly greater efficien-
cy than it could inhibit DNA topoisomerase-I.5 In addi-
tion, FL118 was shown to selectively and independently
inhibit additional anti-apoptotic genes including Mcl-1,
XIAP and cIAP2. In preclinical settings, FL118 showed a
favorable toxicity profile in experimental animals,6 and
an effective antitumor activity against human colon and
head-and-neck tumors in a topoisomerase I- and P53 sta-
tus-independent manner.5,7 The latter is of importance for
MM, since mutations or the loss of the P53 encoding
gene, through the deletion of chromosome 17p, are char-
acteristics of high-risk MM with poor prognosis.8,9
Prompted by these encouraging results, we have
addressed here for the first time the anti-MM activity of
FL118 in vitro and in vivo.  
We first evaluated FL118 against a panel of six MM cell
lines with a different P53 status (Online Supplementary
Table S1). Since stromal cells can induce EM-DR, the
assays were executed in the presence or absence of MM
patient-derived BM mesenchymal stromal cells
(BMMSC). While FL118 showed only minimal toxicity
against BMMSC (Online Supplementary Figure S1), it
exhibited a clear dose-dependent anti-MM activity in the
MM cell lines, independent of the P53 status, with the
half maximal effective concentration (EC50) values rang-
ing from 7.4 nmol/L to 344.8 nmol/L (Figure 1A).
Importantly, lysis of MM cell lines by FL118 was not
reduced, or even increased, in the presence of BMMSC
for five of six MM cell lines, except for a minimal reduc-
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Figure 1. FL118 is effective against MM cell lines regardless of the presence of bone marrow (BM) mesenchymal stromal cells (MSC) and abrogates stromal
cell-induced drug resistance against bortezomib and doxorubicin. (A) Luciferin (LUC)-transduced MM cell lines were treated with serial concentrations of FL118
in the presence or absence of BM mesenchymal stromal cells (BMMSC) derived from 12 MM patients at the time of diagnosis. MM cell viability was determined
by bioluminescence imaging (BLI), after 24 hours of treatment with FL118. The half maximal effective concentration (EC50) values were determined for both
culture conditions from the log dose-response using Graphpad Prism version 7. The differences in the dose response curves were analyzed by nonlinear regres-
sion (*P<0.05; ****P<0.0001). Error bars represent the standard deviation (SD) of four independent experiments executed in duplicate. (B) The MM cell lines
MM1.s and UM9 were treated with serial concentrations of FL118 (1.0-2.0 and 3.1-12.5 nmol/L for MM1.s and UM9 respectively) and with predetermined con-
centrations of bortezomib (BORT; 2 and 4 nmol/L for MM1.s and UM9 respectively) or doxorubicin (DOX; 14 and 108 nmol/L for MM1.s and UM9 respectively)
in the presence or absence of BMMSC or HS-5 for 48 hours. Results are representative of three independent assays. Error bars represent the standard deviation
(SD) of duplicate cultures.
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tion for the cell line UM9. Further analyses indicated that
the efficacy of FL118 to induce lysis in MM cell lines was
not related to the baseline protein expression levels of its
known direct or indirect targets, including Mcl-1,
Survivin, XIAP, Bcl-2, PUMA, or NOXA (Online
Supplementary Figure S2). Rather, the activity of FL118
seemed to correlate with its capacity to modulate these
genes; in three MM cell lines with high, intermediate,
and low FL118 susceptibility, respectively, FL118 promot-
ed pro-apoptotic signaling and cleavage of caspase-3 and
PARP only in the high- and intermediate-susceptible cell
lines but not in the low-susceptible cell line (Online
Supplementary Figure S3).
As previously mentioned, one of the well-described
contributors to therapy resistance in MM is EM-DR.
Crosstalk of MM cells with BMMSC via physical contact
or soluble factors can result in the upregulation of several
anti-apoptotic proteins.2,10,11 Therefore, we questioned
whether FL118 could modulate the stromal cell-mediated
resistance against other anti-MM drugs. Co-culture of
two MM cell lines with BMMSC or, to a larger extent,
with the stromal cell line HS-5 significantly inhibited the
lysis of MM cell lines by two anti-MM drugs, bortezomib
and doxorubicin (Figure 1B). This stroma-cell induced
drug resistance was effectively abrogated by FL118 in a
dose-dependent manner. These observations, in particu-
lar the reversal of stroma-induced bortezomib resistance
by FL118, may be relevant because in combination with
other possible resistance mechanisms, such as protea-
some subunit mutations or increased expression of pro-
teasome subunits, EM-DR also contributes to clinical
bortezomib resistance.12 
To evaluate the activity of FL118 in a preclinical setting,
we assessed its efficacy against primary MM cells present
in BM mononuclear cell (BMMNC) samples derived from
15 newly diagnosed (ND) and 12 relapsed and/or refrac-
tory (RR) MM patients. In these samples we measured
the FL118-induced MM cell lysis by flow cytometry via
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Figure 2. FL118 is more effective in
relapsed and/or refractory (RR) MM as com-
pared to newly diagnosed (ND) MM patients
and it enhances melphalan and bortezomib-
induced MM cell lysis. (A) BM mononuclear
cell (BMMNC) samples from 15 ND and 12
RR MM patients were treated with 100
nmol/L FL118 for 24 hours. Viable CD138+
CD38+ MM cells were enumerated via flow
cytometry. The percentage lysis of MM cells
was calculated relative to untreated sam-
ples. Within the RR MM group, patients with-
out known cytogenetic anomalies (n=5), with
a deletion of chromosome 17p (n=3), and
with intact chromosome 17p (n=4) are
depicted with circles, squares, and triangles,
respectively. The bars indicate the median
values. The differences between groups were
tested using the Mann-Whitney test 
(*P<0.05). (B) Mcl-1 and Survivin expression
levels (Median fluorescence intensity (MFI))
in CD138+ CD38+  MM cells of untreated
BMMNC from seven ND and seven RR
patients were determined by flow cytometry.
The bars indicate the median values. The dif-
ferences between groups were tested using
the Mann-Whitney test (**P<0.01; ns: not
significant). (C) Mcl-1 and Survivin expres-
sion levels (MFI) in CD138+ CD38+ MM cells
that were untreated or treated with FL118 for
16 hours. The differences between groups
were tested using Wilcoxon matched-pairs
rank test (*P<0.05; ns: not significant). Note
that Survivin modulation was more pro-
nounced in RR MM patients P=0.031) com-
pared to ND MM patients (P=0.078). (D)
BMMNC from MM patients were treated with
predetermined suboptimal concentrations of
FL118 (12.5-100 nmol/L) and/or with prede-
termined suboptimal concentrations of mel-
phalan (5-10 mmol/L) (n=10) or bortezomib
(2-3 nmol/L) (n=9) for 48 hours. The
observed lysis levels (obs) upon co-treatment
were compared to the expected lysis levels
(exp), which were calculated with the
assumption that the combinatorial effect is
achieved by additive effects (Bliss-model)
thus using the following formula: % expected
lysis = (% lysis with FL118 + % lysis with the
second drug) - % lysis with FL118 × % lysis
with the second drug. The null hypothesis of
“additive effects” was rejected if the
observed values were significantly different
than the expected values. Bars represent the
median values of the groups. The statistical
differences between the indicated groups
were calculated using the Wilcoxon matched-
pairs rank test (*P<0.05; **P<0.01; ns: not
significant). 
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enumeration of the surviving CD138+ CD38+ MM cells as
reported earlier,13 after incubation with FL118 for 24
hours. In 15 of 27 samples, FL118 induced MM cell lysis
equal or above 20% (Figure 2A). Interestingly, FL118 was
significantly more effective in the samples of RR patients
compared to ND patients. Furthermore, similar to the
results obtained with MM cell lines, anti-MM activity of
FL118 was independent of the P53 status, since among all
well-responsive FL118 patients, there were also three
patients who showed a deletion of chromosome 17p
(Figure 2A).  In an attempt to clarify the superior activity
of FL118 in RR as compared to ND patients, we meas-
ured two FL118 target molecules, Survivin and Mcl-1, in
primary MM cells by flow cytometry. Even though RR
patients showed enhanced Survivin expression as com-
pared to ND patients, the anti-MM efficacy of FL118 was
not associated with the baseline expression of either
Survivin or Mcl-1 (Figure 2B). However, again in agree-
ment with the results from cell lines, the anti-MM effica-
cy of FL118 seemed related to its ability to modulate
these anti-apoptotic proteins, with Survivin modulation
being more pronounced in RR patients compared to ND
patients (Figure 2C). Interestingly, in many FL118-suscep-
tible RR patients, the levels of Survivin expression,
although significantly reduced by FL118, were still rela-
tively higher compared to ND patients. This observation
suggests that RR patients become dependent on elevated
levels of anti-apoptotic proteins for their survival and
may explain why FL118 is more efficient in RR patients
than in ND patients. Alternatively, differential expression
of efflux pumps could explain the differential efficacy of
FL118, but this scenario seems unlikely since recent
reports indicate that FL118 is not a substrate for
ABCG/CRP and MDR1/P-glycoprotein (P-gp) efflux
pumps.7,14 
Since efficacious treatment of MM only has been
achieved through combination therapy, we investigated
whether FL118 could enhance MM cell lysis when com-
bined with currently used anti-MM drugs, including mel-
phalan, bortezomib, lenalidomide, pomalidomide, or
dexamethasone. Assays with MM cell lines suggested at
least an additive activity of FL118 combination with mel-
phalan or bortezomib (Online Supplementary Figure S4). In
primary BMMNC samples, FL118 showed additive
effects with bortezomib and synergistic effects with mel-
phalan (Figure 2D). Noteworthy here is the recently
reported inhibitory activity of FL118 on ERCC6, a critical
regulator of DNA repair.6 This could explain the favorable
combination of FL118 with melphalan and bortezomib,
as both drugs can induce DNA damage. FL118 did not
improve anti-MM activity of immunomodulatory drugs
pomalidomide or lenalidomide and even had antagonistic
effects with dexamethasone (Online Supplementary Figure
S5). Nonetheless, when we used lenalidomide, borte-
zomib and dexamethasone simultaneously, similar to the
clinically applied RVD treatment, addition of FL118
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Figure 3. In vivo anti-tumor activity of FL118. (A) Schematic overview of the experimental design: Hybrid scaffolds, in vitro coated with MSC, were implanted
subcutaneously at the back of RAG2−/−γc−/− mice (four scaffolds per mice) and inoculated with tumors (LUC-transduced MM cell line UM9). After one week, mice
were treated with FL118 or vehicle via intravenous administration, daily for five times (arrowed). (B) Bioluminescense images (BLI) of representative mice per
treatment group at week 1 (before the start of the treatment), week 3 (two weeks after the start of the treatment), and week 8 (end of the experiment). Four
treatment groups included: (1) vehicle control (n=3); (2) 0.05 mg/kg FL118 (n=4); (3) 0.1 mg/kg FL118 (n=4); (4) 0.2 mg/kg FL118 (n=4). (C) Analysis of tumor
loads per treatment group. BLI results are expressed as relative tumor growth with the BLI signal at week 1 set to 100% (indicated by the dashed line). Each
tumor growth curve represents the mean with SD. The statistical differences between mice treated with the vehicle and mice treated with FL118 were calcu-
lated using Kruskal-Wallis ANOVA (*P<0.05; **P<0.01).
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increased MM cell lysis in an additive manner. Possibly,
bortezomib mainly contributed to the favorable combi-
nation of RVD treatment with FL118 and, thereby, neu-
tralized the adverse interactions between dexametha-
sone and FL118. Thus, this multidrug combination could
still be beneficial even though this outcome was not pre-
dicted by individual combination assays. 
Finally, to determine the potential in vivo anti-MM
activity of FL118 we used a unique xenotransplant mouse
model, in which MM tumors were grown in a human-
ized BM niche generated by subcutaneous inoculation of
human MSC-coated scaffolds.15 In this model, treatment
of UM9 cell line-derived MM tumors with FL118 for five
days induced a clear, dose-dependent anti-MM activity
(Figure 3). At the highest dose of 0.2 mg/kg, FL118
reduced the initial tumor volume to 14% and delayed
tumor growth up to five weeks (Figure 3C). At week 8,
this dose resulted in a twenty-fold tumor reduction com-
pared to the control group.
Taken together, our results extend earlier findings
obtained in colon and head-and-neck cancer cells5,7 and
indicate that FL118, with its effects on multiple anti-
apoptotic molecules such as Survivin, Mcl-1, XIAP, and
Bcl-2, could be an effective anti-MM agent. Moreover,
the potency of FL118 to overcome stromal cell-induced
drug resistance could be of importance since EM-DR is
considered a relevant mechanism of clinical resistance to
several drugs including bortezomib. The most interesting
observation may be the high anti-MM efficacy of FL118
especially in RR patients, including patients with P53
dysfunction, a patient group that urgently needs new
therapeutic options. Furthermore, our data suggest that
FL118 could also be beneficial when combined with stan-
dard anti-MM agents such as melphalan, bortezomib,
and the currently applied RVD treatment. The potent
preclinical efficacy of FL118 described here therefore
warrants further evaluation of this novel drug as a thera-
py option for RR MM patients in clinical trials as a single
agent or in combination with currently available anti-
MM agents.
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